NCT03126916 2026-02-27
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
Children's Oncology Group
Phase 3 Recruiting
Clinical Trials
10 trialsNCT04293562 2026-02-24
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
Children's Oncology Group
Phase 3 Recruiting
NCT06647953 2026-02-24
Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma
Children's Oncology Group
Phase 3 Recruiting
NCT03007147 2026-02-23
Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Children's Oncology Group
Phase 3 Active not recruiting
NCT01231906 2026-01-23
Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma
Children's Oncology Group
Phase 3 Completed
NCT00003937 2014-08-05
Combination Chemotherapy Plus Dexrazoxane in Treating Patients With Newly Diagnosed Nonmetastatic Osteosarcoma
Children's Oncology Group
Phase 3 Completed
NCT00005578 2014-07-24
Combination Chemotherapy With or Without Dexrazoxane in Treating Children With Hodgkin's Disease
Children's Oncology Group
Phase 3 Completed
NCT00002827 2013-08-26
Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin's Disease
Children's Oncology Group
Phase 3 Completed
NCT00334867 2013-06-28
Combination Chemotherapy With or Without Topotecan in Treating Patients With Newly Diagnosed Localized Ewing's Sarcoma
Children's Oncology Group
Phase 3 Withdrawn
NCT01230983 2013-06-06
T-Cell #4
Children's Oncology Group
Phase 3 Completed